185.62
price down icon0.01%   -0.00
 
loading
Schlusskurs vom Vortag:
$185.62
Offen:
$185.01
24-Stunden-Volumen:
324.35K
Relative Volume:
0.04
Marktkapitalisierung:
$334.73B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
78.99
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
+0.03%
1M Leistung:
-0.27%
6M Leistung:
+4.45%
1J Leistung:
+8.94%
1-Tages-Spanne:
Value
$184.38
$185.53
1-Wochen-Bereich:
Value
$181.73
$188.99
52-Wochen-Spanne:
Value
$163.52
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Firmenname
Abbvie Inc
Name
Telefon
(847) 932-7900
Name
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Mitarbeiter
55,000
Name
Twitter
@abbvie
Name
Nächster Verdiensttermin
2025-04-25
Name
Neueste SEC-Einreichungen
Name
ABBV's Discussions on Twitter

Vergleichen Sie ABBV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.50 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
780.87 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.61 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.43 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.47 234.21B 53.22B 12.86B 14.85B 6.39

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-14 Herabstufung Citigroup Buy → Neutral
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-05 Herabstufung Daiwa Securities Outperform → Neutral
2024-11-22 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-04 Hochstufung Argus Hold → Buy
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-06-05 Hochstufung HSBC Securities Hold → Buy
2024-05-17 Eingeleitet Cantor Fitzgerald Overweight
2024-01-29 Hochstufung William Blair Mkt Perform → Outperform
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-12-11 Hochstufung Goldman Neutral → Buy
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-30 Hochstufung Barclays Equal Weight → Overweight
2023-10-20 Fortgesetzt UBS Neutral
2023-09-29 Eingeleitet Raymond James Outperform
2023-07-25 Eingeleitet William Blair Mkt Perform
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-05 Herabstufung Argus Buy → Hold
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-22 Herabstufung Wolfe Research Outperform → Peer Perform
2023-02-10 Hochstufung SVB Securities Underperform → Market Perform
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-11-08 Herabstufung Societe Generale Buy → Hold
2022-08-01 Herabstufung Atlantic Equities Overweight → Neutral
2022-05-23 Eingeleitet SVB Leerink Underperform
2022-05-06 Herabstufung Daiwa Securities Outperform → Neutral
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-02-28 Herabstufung UBS Buy → Neutral
2022-02-03 Bestätigt BMO Capital Markets Outperform
2022-02-03 Bestätigt Barclays Equal Weight
2022-02-03 Bestätigt BofA Securities Neutral
2022-02-03 Bestätigt Goldman Neutral
2022-01-13 Eingeleitet Redburn Buy
2022-01-12 Bestätigt BMO Capital Markets Outperform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-11-23 Hochstufung Societe Generale Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2020-11-10 Fortgesetzt Bernstein Outperform
2020-09-29 Eingeleitet Berenberg Hold
2020-06-23 Hochstufung Atlantic Equities Neutral → Overweight
2020-06-09 Hochstufung Wolfe Research Peer Perform → Outperform
2020-06-02 Hochstufung Argus Hold → Buy
2020-05-18 Fortgesetzt BofA/Merrill Neutral
2020-05-12 Hochstufung JP Morgan Neutral → Overweight
2020-05-11 Fortgesetzt Morgan Stanley Overweight
2020-04-20 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-26 Bestätigt Cowen Outperform
2019-09-26 Hochstufung Citigroup Neutral → Buy
2019-08-20 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-27 Hochstufung Wolfe Research Underperform → Peer Perform
2019-06-26 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-05-28 Eingeleitet Goldman Neutral
2019-04-29 Hochstufung BMO Capital Markets Underperform → Market Perform
Alle ansehen

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal of late-stage study - TradingView

Jun 18, 2025
pulisher
Jun 17, 2025

Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie’s $1.6 Billion Break Fee Sidesteps Capital Loss Limit (1) - news.bloombergtax.com

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - Investing News Network

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising P - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy - Crain's Chicago Business

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow (NYSE:ABBV) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

AbbVie says blood cancer drug fails late-stage trial - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie cancer drug misses the mark in trial for new use - Crain's Chicago Business

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie stock dips after cancer drug trial setback - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback with Leukemia Drug Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: trial fails in myelodysplastic syndrome - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Says Myelodysplastic Syndrome Phase 3 Trial Failed to Meet Primary Endpoint - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Highe - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie’s venetoclax fails in phase 3 trial for MDS treatment By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update On VERONA Trial For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Phase 3 VERONA Trial Falls Short: Key Results for Venetoclax MDS Treatment Revealed - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: Margin Clarity, Dividend Durability Awaited (NYSE:ABBV) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie, Chicago Cubs step up to plate to hit a cancer research grand slam - Medical Marketing and Media

Jun 16, 2025

Finanzdaten der Abbvie Inc-Aktie (ABBV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Abbvie Inc-Aktie (ABBV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Mar 31 '25
Sale
210.08
58,832
12,359,504
53,234
drug_manufacturers_general NVO
$68.45
price down icon 0.92%
drug_manufacturers_general JNJ
$153.54
price up icon 0.47%
drug_manufacturers_general NVS
$122.30
price up icon 1.02%
drug_manufacturers_general MRK
$79.06
price down icon 0.06%
$280.45
price up icon 0.68%
Kapitalisierung:     |  Volumen (24h):